Cyclerion Therapeutics (NASDAQ:CYCN) Issues Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Cyclerion Therapeutics (NASDAQ:CYCN) posted its quarterly earnings data on Monday. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.38) by $0.19, FiscalAI reports. The company had revenue of $1.03 million during the quarter, compared to analysts’ expectations of $0.10 million. Cyclerion Therapeutics had a negative net margin of 77.02% and a negative return on equity of 24.61%.

Cyclerion Therapeutics Price Performance

Shares of NASDAQ:CYCN opened at $1.45 on Tuesday. Cyclerion Therapeutics has a 1 year low of $1.03 and a 1 year high of $3.79. The firm has a market capitalization of $5.68 million, a PE ratio of -1.93 and a beta of 0.94. The business’s 50 day moving average price is $1.38 and its 200-day moving average price is $1.69.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new position in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics as of its most recent SEC filing. 75.62% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Monday, December 22nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Cyclerion Therapeutics presently has a consensus rating of “Sell”.

Cyclerion Therapeutics Company Profile

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.